Related Experiment Video
Updated: Oct 20, 2025

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Do mechanisms matter? Comparing cancer treatment strategies across mathematical models and outcome objectives
Cassidy K Buhler1,2, Rebecca S Terry2,3, Kathryn G Link4
1Department of Decision Sciences and MIS, Drexel University, 3220 Market St, Philadelphia, PA 19104, USA.
Abstract:
When eradication is impossible, cancer treatment aims to delay the emergence of resistance while minimizing cancer burden and treatment. Adaptive therapies may achieve these aims, with success based on three assumptions: resistance is costly, sensitive cells compete with resistant cells, and therapy reduces the population of sensitive cells. We use a range of mathematical models and treatment strategies to investigate the tradeoff between controlling cell populations and delaying the emergence of resistance. These models extend game theoretic and competition models with four additional components: 1) an Allee effect where cell populations grow more slowly at low population sizes, 2) healthy cells that compete with cancer cells, 3) immune cells that suppress cancer cells, and 4) resource competition for a growth factor like androgen. In comparing maximum tolerable dose, intermittent treatment, and adaptive therapy strategies, no therapeutic choice robustly breaks the three-way tradeoff among the three therapeutic aims. Almost all models show a tight tradeoff between time to emergence of resistant cells and cancer cell burden, with intermittent and adaptive therapies following identical curves. For most models, some adaptive therapies delay overall tumor growth more than intermittent therapies, but at the cost of higher cell populations. The Allee effect breaks these relationships, with some adaptive therapies performing poorly due to their failure to treat sufficiently to drive populations below the threshold. When eradication is impossible, no treatment can simultaneously delay emergence of resistance, limit total cancer cell numbers, and minimize treatment. Simple mathematical models can play a role in designing the next generation of therapies that balance these competing objectives.
Insights
Cancer treatment aims to balance controlling tumor burden and delaying resistance when eradication is impossible. Mathematical models reveal a tradeoff, with no single strategy optimizing all goals.
Area of Science:
- Mathematical Oncology
- Cancer Therapeutics
- Evolutionary Dynamics
Background:
- Cancer treatment often aims to manage, not cure, by delaying resistance and reducing tumor burden.
- Adaptive therapies are proposed to balance these goals, relying on assumptions about resistance cost and cell competition.
Purpose of the Study:
- Investigate the tradeoff between controlling cancer cell populations and delaying the emergence of treatment resistance.
- Evaluate various treatment strategies, including maximum tolerable dose, intermittent treatment, and adaptive therapy.
Main Methods:
- Utilized a range of mathematical models, extending game theoretic and competition models.
- Incorporated factors like the Allee effect, competition with healthy cells, immune suppression, and resource competition.
Main Results:
- No therapeutic strategy robustly overcame the tradeoff between delaying resistance and minimizing cancer burden.
- Intermittent and adaptive therapies often showed similar performance curves regarding resistance emergence and cell burden.
- The Allee effect disrupted expected outcomes, with some adaptive therapies performing poorly.
Conclusions:
- When cancer eradication is impossible, no single treatment can simultaneously delay resistance, limit cancer burden, and minimize treatment toxicity.
- Mathematical modeling is crucial for designing next-generation therapies that balance competing objectives in cancer management.
More Related Videos
Related Concept Videos
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Kaplan-Meier Approach
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

